This has also likely contributed to the stock price soaring. A 0.3% formulation of Zoryve cream is approved for treating plaque psoriasis in patients six years and older and for seborrheic ...

Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on January 13.Invest with Confidence: ...

This aligns with the broader analyst consensus, as revealed by InvestingPro data, with price targets ranging from $12 to $29. According to the firm, Arcutis' Zoryve product line, which includes ...

Arcutis Biotherapeutics (ARQT) announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for ZORYVE cream 0.05%, a once-daily, next generation ...

Uy Ear has given his Buy rating due to a combination of factors, primarily driven by the strong performance of Arcutis Biotherapeutics’ Zoryve franchise ... with a $20.00 price target.